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EBI2, aka GPR183, is a G-couple receptor originally identified in 1993 as one of main
genes induced in Burkitt’s lymphoma cell line BL41 by Epstein–Barr virus (EBV) infection.
After it was reported in 2009 that the receptor played a key role in regulating B cell
migration and responses, we initiated an effort in looking for its endogenous ligand. In
2011 we and another group reported the identification of 7α, 25-dihydroxyxcholesterol
(7α, 25-OHC), an oxysterol, as the likely physiological ligand of EBI2. A few subsequently
published studies further elucidated how 7α, 25-OHC bound to EBI2, and how a
gradient of 7α, 25-OHC could be generated in vivo and regulated migration, activation,
and functions of B cells, T cells, dendritic cells (DCs), monocytes/macrophages, and
astrocytes. The identification of 7α, 25-OHC as a G protein-coupled receptor ligand
revealed a previously unknown signaling system of oxysterols, a class of molecules
which exert profound biological functions. Dysregulation of the synthesis or functions
of these molecules is believed to contribute to inflammation and autoimmune diseases,
cardiovascular diseases, neurodegenerative diseases, cancer as well as metabolic
diseases such as diabetes, obesity, and dyslipidemia. Therefore EBI2 may represent
a promising target for therapeutic interventions for human diseases.
Keywords: EBI2, 7α, 25-OHC
Introduction
G protein-coupled receptors (GPCRs), through ligation and activation by cognate ligands, regulate
key cellular functions including generation, homeostasis, activation, diﬀerentiation, proliferation,
migration. Functional dysregulation of these receptors often lead to pathogenesis in many human
diseases. Therefore these receptors represent a class of highly druggable targets, which counted for
a signiﬁcant number of top marketed drugs in recent years (Andrews et al., 2014). Among ∼800
predicted GPCR genes, over 600 belong to a largest group of Rhodopsin-like family (Class A) and
about half of which are believed to be liganded receptors. For this group liganded receptors, there
are still ∼100 GPCR whose cognate ligands have not been identiﬁed, which are of high interest for
discovering novel biological mechanisms and potential drug targets. At Janssen, our past eﬀorts
have de-orphanized a number of these orphans including H3, H4 (Lovenberg et al., 1999; Liu et al.,
2001, 2003, 2005, 2009; Hannedouche et al., 2011).
EBI2, aka, GPR183, was originally identiﬁed in Birkenbach et al. (1993) as one of main genes
induced in Burkitt’s lymphoma cell line BL41 by Epstein–Barr virus (EBV) infection. Gatto et al.
(2009) and Pereira et al. (2009), two groups independently reported that the receptor played a
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key role in regulating B cell migration and responses, which
prompted our interest and eﬀort in looking for its endogenous
ligand. Two years later, our group and the other (Hannedouche
et al., 2011; Liu et al., 2011) independently discovered and
reported the identiﬁcation of 7α, 25-dihydroxycholesterol (7α,
25-OHC) as the endogenous ligand for EBI2. This was further
supported by subsequent studies (Benned-Jensen et al., 2012;
Zhang et al., 2012) detailing how 7α, 25-OHC binds and acti-
vates EBI2, and how the oxysterol is produced and how a
gradient of 7α, 25-OHC is generated in vivo (Yi et al., 2012).
Besides its role in regulating immune cell migration (Table 1),
there were also published evidences linking EBI2 with human
diseases, including type 1 diabetes (T1D; Heinig et al., 2010),
multiple sclerosis (MS; Chalmin et al., 2015), and cancer cell
proliferation (Benned-Jensen et al., 2011). Therefore EBI2 may
represent a promising target for a number of indications such as
inﬂammatory or autoimmune diseases, metabolism diseases, and
cancer.
In this review, we describe our de-orphanization eﬀort lead-
ing to the identiﬁcation of 7α, 25-OHC, summarize published
data related to EBI2 receptor function and in human diseases, and
small molecule EBI2 modulators reported to date.
Role of EBI2 in B Cells Migration
Secondary lymphoid tissues such as spleen and lymph nodes
consist of distinct functional compartments such as B cell fol-
licles that surround a central T cells zone. In spleen, folli-
cles are also surrounded by marginal zone where marginal
zone innate B cells localize. Functional compartmentation of
these tissues is controlled by spatial and temporal expression of
chemokines by stromal or resident cells, and chemokine recep-
tors by migratory lymphocytes including T cells, B cells, and
DC. For example, naïve B cells express high level of CXCR5,
home to follicles via gradient of CXCL13 produced by follic-
ular stromal cells. Upon antigen encounter, activated B cells
upregulate the expression of CCR7, and migrate toward T-B
boundary in responding to CCL19 and CCL21 which are pro-
duced by cells within T cell zone. As B cells response progresses,
diﬀerentiating B cells within germinal centers regulate expres-
sion of another receptor CXCR4, the receptor for CXCL12,
which segregate B cells into light zone and dark zone, and also
direct migration of plasma cells to splenic red pulp and bone
marrow.
Gatto et al. (2009) and Pereira et al. (2009) two groups
reported that EBI2 played a critical role in regulating B cell
migration during immune activation. It appeared that naïve
B cells express high level of EBI2, which was further upreg-
ulated upon B cell activation, and interestingly expression of
EBI2 was signiﬁcantly down-regulated in germinal center B
cells. Employing B cells which were deﬁcient or overexpress-
ing EBI2, the authors demonstrated that increased expression
of EBI2 directed activated B cell migration to outer follicu-
lar areas; and down-regulation of EBI2 was a prerequisite for
migration into central follicular areas to form germinal centers.
Although it appeared that EBI2 did not directly aﬀect activation
and proliferation of B cells, B cells deﬁcient in EBI2 nonethe-
less led to defective antibody responses in vivo. These seminal
ﬁndings clearly suggested EBI2 played a role in B cells migra-
tion. Therefore, together with CXCR5, CXCR4, and CCR7, EBI2
appeared to be another key chemotactic receptor to direct B cell
migration and positioning within secondary lymphoid tissues.
This notion was further demonstrated later by a study using com-
pound knockout mice in which one, two or all three of receptors
including CXCR5, CCR7, and EBI2 were knocked out (Gatto
et al., 2011).
De-orphanization of EBI2
In 2011, we and another group (Hannedouche et al., 2011;
Liu et al., 2011), independently identiﬁed 7α, 25-OHC as the
endogenous ligand for EBI2 and demonstrated that the oxysterol
functioned as a chemotactic molecule for B cell migration.
To identify EBI2 ligand, the two groups took similar
approaches starting from detecting EBI2-speciﬁc activity in par-
tially puriﬁed rat, porcine, or sheep tissue extracts, followed by
chromatography–mass spectrometry (GCMS) and NMR meth-
ods to identify the active molecule as an oxysterol. While
Hannedouche et al. (2011) directly showed the ﬁnal puriﬁed
activity as 7α, 25-OHC, we took a slightly diﬀerent approach.
Once we identiﬁed certain EBI2 active oxysterols such as
7α-OHC, 7β-OHC, and 25-OHC through GCMS and NMR, we
acquired and tested a number of commercially available oxys-
terols. The results led us to speculate that 7α, 25-OHC was likely
the most potent EBI2 agonist, which was conﬁrmed using a syn-
thesized compound. We then further showed that starting from
extract of a single mouse spleen, the only signiﬁcant activity
which could be puriﬁed and detected co-migrated in GCMS with
TABLE 1 | Function of EBI2 in immune cells.
Cell types Function of EBI2 Reference
B cells Migration Gatto et al. (2009, 2011), Pereira et al. (2009), Hannedouche et al. (2011),
Liu et al. (2011)
Enhanced proliferation Benned-Jensen et al. (2011)
T cells Migration Hannedouche et al. (2011), Liu et al. (2011), Chalmin et al. (2015)
DC, monocyte Migration Hannedouche et al. (2011), Liu et al. (2011), Gatto et al. (2013), Yi and
Cyster (2013), Gessier et al. (2014), Preuss et al. (2014)
Negative regulation of type I interferon Heinig et al. (2010), Chiang et al. (2013)
Astrocytes Migration Rutkowska et al. (2015)
Frontiers in Pharmacology | www.frontiersin.org 2 March 2015 | Volume 6 | Article 60
Sun and Liu EBI2 in immune regulation and diseases
the synthetic 7α, 25-OHC, and the identity of the active puriﬁed
fraction was further conﬁrmed by NMR.
Both groups demonstrated that 7α, 25-OHC showed satu-
rated binding to EBI2 in radioligand binding assays. 7α, 25-OHC
was highly potent in binding and activating human EBI2 in
cells (Figure 1; Kd 450 pM; GTPγS EC50 140 pM), and cou-
pled to Gi/o proteins (e.g., inhibition of cAMP production IC50,
2 nM). Consistent with previously ﬁndings indicting a role of
EBI2 in driving B cell migration, 7α, 25-OHC induced migra-
tion of mouse and human B cells in vitro, and interestingly T
cells and DC as well, in an EBI2-dependent manner. In cells, lig-
ation of EBI2 by 7α, 25-OHC induced receptor internalization
and desensitization. Thus, pretreatment of mouse B cells with
7α, 25-OHC for 1 h in vitro rendered these cells refractory to
migration induced by 7α, 25-OHC, and interestingly a few other
chemokines such as CXCL12, CXCL13, and CCL19/21 as well.
Further experiments showed that the expression of EBI2 and
also the two enzymes required for synthesis of 7α, 25-OHC
biosynthesis, i.e., cholesterol 25-hydrxylase (Ch25H) and oxys-
terol 7α-hydroxylase (Cyp7B1) was highly modulated by inﬂam-
matory stimuli such as LPS in various immune cells such as
B cells, T cells, and dendritic cells (DCs) in vitro as well as
in vivo in mice. In a B cell adoptive transfer model, we showed
that 7α, 25-OHC-pretreatment of B cells (therefore desensitized)
reduced homing of these cells into follicles after adoptive transfer,
suggesting EBI2 also plays a role in B cell homing to secondary
lymphoid tissues.
To demonstrate the role of 7α, 25-OHC in vivo, we employed a
model in which host mice were dosed with Clotrimazole, an anti-
fungi compound with known Cyp7B1 inhibition activity which
was shown to signiﬁcantly reduce level of 7α, 25-OHC in vitro
and in vivo. In comparison, Hannedouche et al. (2011) employed
FIGURE 1 | Structures of selected E1312 agonists and antagonists, and their activities. Key compound activities and associated publications were listed.
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Ch25HKOmice as hosts which as expected were deﬁcient in pro-
duction of 7α, 25-OHC. In both models adoptively transferred
wild-type B cells showed identical migration pattern as those for
Ebi2-deﬁcient B cells adoptively transferred into vehicle-treated
or wild-type hosts. Thus, for example, our studies showed that
adoptively transferred wild-type B cells migrated into and local-
ized throughout splenic follicles in normal hosts; however, in
Clotrimazole-treated hosts, a much greater percentage of trans-
ferred B cells was localized at the T-B boundary, presumably due
to CCR7-dependent migration of these B cells and lack of EBI2-
driven migration at the same time. In addition, Hannedouche
et al. (2011) further showed that, as a functional consequence,
plasma cell response in Ch25H KO mice was similarly defective
as that in Ebi2-deﬁcient mice.
A subsequent study by Yi et al. (2012) suggested that lymphoid
stromal cells were the main Ch25H- and Cyp7B1-expressing cells
and were responsible for production of 7α, 25-OHC in vivo. In
addition, the group also demonstrated that the same cells were
likely also responsible for degradation of 7α, 25-OHC by express-
ing HSD3B7 which converts 7α, 25-OHC into a 3-oxo derivative.
Importantly, deﬁciency in any three of these enzymes aﬀected B
cell positioning in vivo, and resulted in defective T cell-dependent
plasma cell response.
Taken together, the data from these studies clearly demon-
strated that 7α, 25-OHC was the endogenous EBI2 ligand driving
B cells migration, and modulating B cell antibody responses
in vivo.
Binding of 7α, 25-OHC to EBI2
Since EBI2 is the ﬁrst GPCR known to bind and be activated by an
oxysterol, we carried out and later published (Zhang et al., 2012)
a study to understand the molecular and structural basis for its
ligand-dependent activation.
Using a site-directed mutagenesis approach, we generated
mutated receptors that carried single amino acid substitutions.
The pharmacological proﬁles of these mutant receptors were
characterized by measuring receptor expression, radioligand
binding, and receptor activation. Within the highly variable
extracellular regions, we compared sequences from human, rat
and mouse, and selected a number of conserved residues for
mutagenesis study. This led to identiﬁcation of Glu183 in ECL2,
Ala-substitution of which resulted in signiﬁcant reduction of
ligand binding and ∼50-fold potency reduction.
Transmembrane (TM) regions of GPCR are structurally con-
served and the helical cores are thought to make up the ligand
binding pocket. We aligned EBI2 TM sequences with those of
GPCR with a deﬁned ligand binding pocket, and selected key
residues for mutagenesis analysis. Among key residues identi-
ﬁed by these analyses, Arg87 (TM2) to Ala, or Trp and Asn114
to Ala resulted in diminished receptor binding and ∼500 fold or
more reduction in ligand potency. A number of other residues
that showed reduced ligand binding and receptor function after
Ala substitution included Tyr112 and Tyr116 of TM3; Leu197
of TM5; Tyr260, His216, and Ile264 of TM6; Val294 and M297
of TM7. Moreover, Ala substitution of Asp77 showed no eﬀect
on ligand binding, however, was found to severely reduce recep-
tor activation suggesting the residue was important for receptor
activation or signal transduction.
By examining various analogs of 7α, 25-OHC in EBI2-
dependent assays, we showed that all three hydroxyl groups at
3′, 7′α, and 25′ were required for receptor binding and activation.
Using a hybrid β2AR-CXCR4 structure as a template, we created
a homology model for EBI2. Optimization of docking of 7α, 25-
OHC into the putative ligand binding pocket of the EBI2 model
structure suggested that residues Arg87, Asn114, and Glu183
interact with 7′α-, 25′-, and 3′-hydroxyl group respectively.
In addition, our analysis also suggested that Cys104 (ECL1)
and Cys181 (ECL2) form the classic disulﬁde bond observed
in many other GPCR, while Cys21 (N-terminal) and Cys280
(ECL3) may form a second disulﬁde bridge. This pattern of
extracellular disulﬁde bridges appeared to be the same as in
CXCR4. This proposed model of two disulﬁde bridges has impor-
tant functional implications. Because of the Cys104-Cys181 link,
ECL2 is brought close to the TM domain and may form a cap
over the putative ligand binding site. As a result, Glu183 with
ECL2 is positioned within the ligand binding domain, repre-
senting the best candidate forming interaction with 3′-hydroxyl
group of 7α, 25-OHC. This notion was further supported by
the inactivity of 7α, 27-dihydroxy-4-cholesten-3-one where a
ketone interacting with the carboxylate would be energetically
unfavorable.
Another group (Benned-Jensen et al., 2012) published a sim-
ilar mutagenesis study around the same time. In that study, the
authors focused on residues facing the main putative ligand bind-
ing pocket for mutagenesis analysis, which led to identiﬁcation
of four key residues required for 7α, 25-OHC binding: Arg87,
Tyr112 and Tyr116, and Tyr260. These ﬁndings are consistent
with what we reported. Docking modeling by these authors
suggested a diﬀerent model from ours, i.e., Y116 interacts with 3′-
hydroxyl group, Y260 with 7′α-hydroxyl group, and Y260 directly
or indirectly with 25′-hydroxyl group.
Together, these two studies started to shed some insights on
how an oxysterol ligand could bind and activate a GPCR, which
may potentially beneﬁt discovery of novel EBI2 modulators.
Role of EBI2 in Immune Responses
and Diseases
It is now clear that EBI2 plays important roles in modulating acti-
vation and controls migration of various immune cells (Table 1).
The function of EBI2 in B cells in vivo appears to be largely depen-
dent on directing B cell migration and positioning in secondary
lymphoid tissues. As described above, EBI2 deﬁciency or deﬁ-
ciency in 7α, 25-OHC biosynthesis resulted in reduce plasma cell
responses. In vitro, EBI2-deﬁcient mouse B cells did not show
overt deﬁciency in activation including proliferation or upregu-
lation of cell surface marker such as CD86 (Gatto et al., 2009).
Neither did we observe much eﬀect with 7α, 25-OHC when
added to B cell cultures (unpublished data). However, it was
reported that B cells from transgenic mice with overexpression
of human EBI2 showed enhanced antibody-induced proliferation
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(Benned-Jensen et al., 2011). Therefore, it remains a possibility
that EBI2 ligation may directly aﬀect certain aspect of B cell acti-
vation. To this end, it was speculated that dysregulation of EBI2
expression might contribute in B cell malignancies (Benned-
Jensen et al., 2011, 2013). For example, EBI2 expression was
increased in post-transplantation lymphoproliferative diseases
(PTLDs; Craig et al., 2007). Therefore, it was proposed that an
EBI2 antagonist might oﬀer therapeutic beneﬁt in blocking pro-
liferation of EBV-transformed B cell lymphomas (Benned-Jensen
et al., 2011, 2013).
In addition to B cells, EBI2 was also found to be expressed
in T cells, and DC/monocytes (Hannedouche et al., 2011; Liu
et al., 2011). These ﬁndings suggested that EBI2 may play key
roles in regulating other immune cells. In vitro, 7α, 25-OHC
clearly induced migration of mouse and human T cells and
CD11c+ DC/monocytes. One recent report (Chalmin et al., 2015)
showed that Ch25h deﬁciency led to signiﬁcantly attenuated
disease in mouse experimental autoimmune encephalomyelitis
(EAE). a model of MS, The authors showed that there was a
critical involvement for oxysterols in recruiting leukocytes into
the inﬂamed central nervous system (CNS) and proposed that
7α, 25-OHC preferentially promoted EBI2-dependent migration
of activated CD44+CD4+ T cells. In a related study (Wanke
et al., 2014), using a novel reporter-knockin/knockout mouse
model, the authors showed that pathogenic Th1 and Th17 cells
expressed EBI2 within inﬂamed CNS, while Treg cells showed a
bipartite expression. Using a transfer model of EAE, the authors
showed that EBI2-deﬁcient Th17 cell displayed a signiﬁcantly
delayed pathogenesis compared to wild-type Th17 cells. Taken
together, these studies suggested EBI2-dependent migration of
T cells might play a role in pathogenesis in autoimmune disease
such as MS.
EBI2 also appeared to play an important role in control-
ling DC migration and homeostasis in mice. Two groups (Gatto
et al., 2013; Yi and Cyster, 2013) independently reported that
mouse splenic CD4+ DC highly expressed EBI2 and migrated
in response to 7α, 25-OHC. In mice which were deﬁcient in
EBI2 or 7α, 25-OHC biosynthesis, there was a reduced frequency
of splenic CD4+ DC number. The authors further showed that
the deﬁciency was likely due to defective CD4+ DC migration
as there was defective positioning of remaining CD4+ DC to
marginal zone bridging channels and EBI2 did not aﬀect devel-
opment of DC or DC survival. As one of the main functions of
CD4+ DC in the marginal zone bridging channels was to pro-
mote DC encounter of blood-borne particulate antigens, EBI2
deﬁciency in these speciﬁc DC led to defects in both activation
of helper T cells and induction of antibody response to this type
of antigens.
Expression of EBI2, Ch25H, and Cyp7B1 was found to be
highly unregulated in a number of inﬂammatory diseases, includ-
ing chronic rhinosinusitis (CRS; Hulse et al., 2013). Nasal polyps
from CRS patients showed increased expression of EBI2 which
was positively correlated with the expression of plasma cell mark-
ers (such as CD138 and B lymphocyte-induced maturation pro-
tein) in sinus tissue. Upregulation of Cyp7B1 was observed in
inﬂamed joints in collagen-induced arthritis model (Dulos et al.,
2004), a mouse model of rheumatoid arthritis (RA). The same
ﬁndings applied to ﬁbroblast-like synoviocytes obtained from RA
synovial tissues (Dulos et al., 2005), which suggested that EBI2
might also play a role in RA. Interestingly, supporting this notion,
the CYP7B1 inhibitor Clotrimazole was tested in RA and showed
some eﬃcacy (Wojtulewski et al., 1980).
Human primary macrophages were also reported (Preuss
et al., 2014) to express EBI2, Ch25H, and Cyp7B1. In cul-
tured monocyte-derived macrophages, LPS triggered a strong
up-regulation of Ch25H and Cyp7B1 and a transient increase in
EBI2 expression. Ligation of EBI2 in cultured macrophages led
to calcium mobilization and cell migration. Culture supernatants
of LPS-stimulated macrophages were able to activate EBI2 sig-
naling indicating that these cells produced 7α, 25-OHC upon
LPS-induction of Ch25H and Cyp7B1.
A genome-wide association study using both rat and human
data published in Heinig et al. (2010) implicated EBI2 as a reg-
ulator of an interferon regulatory factor 7 (IRF)-driven inﬂam-
matory network (IDIN), which was associated with susceptibility
of T1D. The human locus controlling IDIN was associated with
the risk of T1D at a single nucleotide polymorphism rs9585056,
which was also associated with increased EBI2 expression. siRNA
knockdown of EBI2 in rat macrophages increased expression
of Irf7 and IDIN genes. Another study (Chiang et al., 2013)
demonstrated that EBI2 negatively regulated type I interferon
(IFN) responses in plasmacytoid DC and CD11b+ myeloid cells.
EBI2 deﬁciency led to increased production of type I interferon
induced by TLR ligands in vitro as well as in vivo. Therefore,
it will be interesting to explore whether dysregulation of EBI2
plays a role in pathogenesis of certain autoimmune disease such
as lupus, Sjogren’s syndrome in which type I interferon is impli-
cated (Swiecki and Colonna, 2011). Oxysterols and oxysterol
sensing receptors have been shown to modulate metabolism (Gill
et al., 2008; Raychaudhuri and Prinz, 2010) and may play roles in
metabolic disease such as diabetes, obesity, and dyslipidemia. The
link between EBI2 and T1D suggested that EBI2 may also have a
similar role.
One group (Rutkowska et al., 2015) recently showed that
human and mouse astrocytes express EBI2 and the enzymes
necessary for synthesis and degradation of 7α, 25-OHC. In astro-
cytes, EBI2 activation stimulates ERK phosphorylation, Ca2+
signaling and induces cellular migration. In addition, activation
EBI2 prevents lysophosphatidylcholine (LPC)-induced demyeli-
nation in cerebellar slices. These results suggested that EBI2 is
involved in glial cell function and modulation of this receptor
may be beneﬁcial in neuroinﬂammatory or neurodegenerative
disorders.
EBI2 Modulators
As described above, it has been demonstrated that EBI2 serves as
a key chemotactic receptor for B cells, T cells and DC, modulat-
ing both T cell and B cell response to blood-borne antigens. The
expression of EBI2 and enzymes for 7α, 25-OHC is upregulated in
inﬂammatory diseases, and dysregulation of EBI2may contribute
to B cell malignancies, and certain autoimmune diseases such as
T1D, RA, lupus, andMS. Therefore it is of interest to discover and
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develop EBI2 modulators and test for their therapeutic potentials
in preclinical models and in patients.
Simultaneous to discovery of 7α, 25-OHC as the endogenous
EBI2 ligand, one group (Benned-Jensen et al., 2011) reported the
identiﬁcation and characterization of a small molecule inverse
agonist, GSK682753A (Figure 1), which blocked the apparent
constitutive activity of EBI2 receptor in a recombinant sys-
tem. It was later (Benned-Jensen et al., 2013) shown that the
compound was actually a potent EBI2 antagonist, blocking 7α,
25-OHC induced EBI2 activation in vitro. A number of com-
pounds were also identiﬁed using a uHTS screen at the Sanford-
Burnham Center for Chemical Genomics which inhibited 7α,
25-OHC-mediated β-arrestin recruitment (PubChem BioAssay
ID: 651636).
Another group (Gessier et al., 2014) recently reported the
identiﬁcation of a small molecule agonist NIBR51 (Figure 1;
hEBI2 EC50 ∼2 μM) from screening about 100 K compounds
in an EBI2-dependent recombinant assay. Using this ago-
nist, the group rescreened the same library and identiﬁed a
small molecule antagonists NIBR127 (Figure 1) which bind to
EBI2 with high aﬃnity (human EBI2 EC50 83 nM) and good
potency in receptor activation (hEBI2 Ca2+ IC50 196 nM).
A subsequent medicinal chemistry eﬀort using NIBR127 as
a starting point led to NIBR189 (Figure 1) with signiﬁcant
improved potency in EBI2 receptor activation (hEBI2 Ca2+
IC50 11 nM). Further pharmacological characterization sug-
gested that NIBR189 was a potent and selective EBI2 antag-
onist with pharmacokinetic properties which should allow for
in vitro and in vivo experiments. To this end, it was noted by
the authors that much of initial testing was directed toward
paradigms of autoimmune disorders. Because of the demon-
strated activity of EBI2 in monocytes as described above, it
was proposed by the authors to test the EBI2 antagonist in
paradigms relevant for cardiovascular diseases (Gessier et al.,
2014).
Concluding Remarks
The identiﬁcation of 7α, 25-OHC as the endogenous EBI2 lig-
and uncovered a previously unknown role for oxysterols, a class
of molecules which exert profound biological eﬀects. Work pub-
lished by a number of groups including ours in last few years
showed that EBI2 and key enzymes in producing 7α, 25-OHC
were highly regulated during inﬂammation, and might play key
roles in pathogenesis of certain human diseases such as to inﬂam-
mation and autoimmune diseases, neurodegenerative disease,
cardiovascular diseases, cancers, as well as metabolic diseases
such as diabetes, obesity, and dyslipidemia. Therefore EBI2 may
represent a promising target for therapeutic interventions.
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